SIAH2 antagonizes TYK2-STAT3 signaling in lung carcinoma cells
Author(s) -
Sylvia Müller,
Yuan Chen,
Torsten Ginter,
Claudia Schäfer,
Marc Buchwald,
Lienhard M. Schmitz,
Jana Klitzsch,
Alexander Schütz,
Andrea Haitel,
Katharina Schmid,
Richard Moriggl,
Lukas Kenner,
Karlheinz Friedrich,
Claude Haan,
Iver Petersen,
Thorsten Heinzel,
Oliver H. Krämer
Publication year - 2014
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.1899
Subject(s) - cancer research , tyrosine kinase 2 , lung cancer , carcinogenesis , stat3 , janus kinase , phosphorylation , signal transduction , biology , tyrosine phosphorylation , janus kinase 2 , tyrosine kinase , cancer , medicine , microbiology and biotechnology , pathology , receptor , biochemistry , genetics , platelet derived growth factor receptor , growth factor
The Janus tyrosine kinases JAK1-3 and tyrosine kinase-2 (TYK2) are frequently hyperactivated in tumors. In lung cancers JAK1 and JAK2 induce oncogenic signaling through STAT3. A putative role of TYK2 in these tumors has not been reported. Here, we show a previously not recognized TYK2-STAT3 signaling node in lung cancer cells. We reveal that the E3 ubiquitin ligase seven-in-absentia-2 (SIAH2) accelerates the proteasomal degradation of TYK2. This mechanism consequently suppresses the activation of STAT3. In agreement with these data the analysis of primary non-small-cell lung cancer (NSCLC) samples from three patient cohorts revealed that compared to lung adenocarcinoma (ADC), lung squamous cell carcinoma (SCC) show significantly higher levels of SIAH2 and reduced STAT3 phosphorylation levels. Thus, SIAH2 is a novel molecular marker for SCC. We further demonstrate that an activation of the oncologically relevant transcription factor p53 in lung cancer cells induces SIAH2, depletes TYK2, and abrogates the tyrosine phosphorylation of STAT1 and STAT3. This mechanism appears to be different from the inhibition of phosphorylated JAKs through the suppressor of cytokine signaling (SOCS) proteins. Our study may help to identify molecular mechanisms affecting lung carcinogenesis and potential therapeutic targets.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom